Relationship Between Serum Parathyroid Hormone and Trace Elements (Serum Zinc and Magnesium) in Hemodialyzed Chronic Renal Failure Children

2008 ◽  
Vol 128 (2) ◽  
pp. 128-134 ◽  
Author(s):  
Azza A. El Tayeb ◽  
Nashwa A. Abd El-Mottaleb ◽  
Ebtihal A. Abdel Aziz
Keyword(s):  
Renal Failure ◽  
Trace Elements ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Serum Zinc ◽  
Serum Parathyroid Hormone

Association between vitamin D receptor Fokl polymorphism and serum parathyroid hormone level in patients with chronic renal failure

2005 ◽  
Vol 28 (4) ◽  
pp. 117-121 ◽  
Author(s):  
E. Vigo Gago ◽  
C. Cadarso-Suárez ◽  
R. Perez-Fernandez ◽  
R. Romero Burgos ◽  
J. Devesa Mugica ◽  
...  
Keyword(s):  
Vitamin D ◽  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Vitamin D Receptor ◽  
Hormone Level ◽  
Parathyroid Hormone Level ◽  
Serum Parathyroid Hormone

scholarly journals Study of prevalence of secondary hyperparathyroidism in chronic renal failure in hadoti region

2019 ◽  
Vol 7 (8) ◽  
pp. 2903
Author(s):  
Chiranjee Lal Dayma ◽  
Devendra Ajmera ◽  
Shiv Charan Jelia ◽  
Pankaj Jain
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Secondary Hyperparathyroidism ◽  
Serum Calcium ◽  
Calcium Level ◽  
Serum Calcium Level ◽  
Hormone Level ◽  
Serum Parathyroid Hormone ◽  
The Difference

Background: Secondary hyperparathyroidism is known and early complication of chronic renal failure patients. Aim of this study was to assess the prevalence of secondary hyperparathyroidism and correlation between serum parathyroid hormone level with biochemical parameters in renal failure patients in tertiary care hospital in Kota, Rajasthan.Methods: A cross sectional observational study was carried out in 50 patients who had creatinine clearance of 30ml/min/1.73m2 or less for greater than 6 weeks attended the OPD of department of General Medicine, New Medical College hospital, Kota, Rajasthan from May 2018 to November 2018. Investigations like complete blood count, renal function test, urine routine microscopy and USG abdomen with serum parathyroid hormone, serum phosphorus, serum calcium levels were done. Serum parathyroid hormone level was done by calorimetric method.Results: The prevalence of secondary hyperparathyroidism in our study was 72%.In hyperparathyroidism patient’s serum calcium level was low and the difference was highly significant (p<0.001). There is negative correlation between S.PTH and S. calcium level (r=-0.536). Mean serum calcium level in our study is 1.6mmol/l. In hyperparathyroidism patient’s serum phosphate level was high and the difference was highly significant (p<0.001). There was positive correlation between S.PTH and S.PO4 level (r=0.402). Mean serum phosphorus level in our study is 5.7 mg/dl. Prevalence of hyperparathyroidism was high among CRF patients with normal BP than hypertensive patients and with normal sugar than diabetics but the difference in proportion was not significant (p=0.87, p=0.98 respectively). 90% patients were on haemodialysis while 10% patients were on conservative management.Conclusions: Early detection of secondary hyperparathyroidism in chronic renal failure patients can reduce its complications like bone fracture and cardiovascular complications.

The Effect of Aluminium Hydroxide on Calcium, Phosphorus and Aluminium Balances, the Serum Parathyroid Hormone Concentration and the Aluminium Content of Bone in Patients with Chronic Renal Failure

1972 ◽  
Vol 43 (4) ◽  
pp. 519-531 ◽  
Author(s):  
E. M. Clarkson ◽  
V. A. Luck ◽  
W. V. Hynson ◽  
R. R. Bailey ◽  
J. B. Eastwood ◽  
...  
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Aluminium Hydroxide ◽  
Plasma Calcium ◽  
Aluminium Content ◽  
Serum Parathyroid Hormone ◽  
Calcium Phosphorus ◽  
Aluminium Hydroxide Gel ◽  
Plasma Phosphorus

1. Eight patients with chronic renal failure (creatinine clearance 4·9–22·0 ml/min) were given 75–150 ml of aluminium hydroxide gel (‘Aludrox’) daily for 20–32 days. 2. In all patients there was a decrease in plasma phosphorus. The phosphorus balance became more negative in four and less positive in one, remained unchanged in two, and became positive in one. 3. Patients absorbed 100–568 mg of aluminium daily. In two of three patients the content of aluminium in the iliac bone increased but not above normal values. 4. The concentration of parathyroid hormone was decreased by aluminium hydroxide therapy in three patients in whom there was an increase in plasma calcium and in one other patient in whom plasma calcium did not change.

Serum parathyroid hormone concentration in chronic renal failure patients on maintenance haemodialysis

1974 ◽  
Vol 57 (1) ◽  
pp. 83-89 ◽  
Author(s):  
M.R. Wills ◽  
Angela Fairney ◽  
Z. Varghese ◽  
G.L.V. Tatler ◽  
Rosemarie A. Baillod ◽  
...  
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Hormone Concentration ◽  
Serum Parathyroid Hormone ◽  
Maintenance Haemodialysis

scholarly journals Role of parathyroid hormone in the glucose intolerance of chronic renal failure.

1985 ◽  
Vol 75 (3) ◽  
pp. 1037-1044 ◽  
Author(s):  
M Akmal ◽  
S G Massry ◽  
D A Goldstein ◽  
P Fanti ◽  
A Weisz ◽  
...  
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Glucose Intolerance

scholarly journals Parathyroid hormone secretion in chronic renal failure

1996 ◽  
Vol 50 (5) ◽  
pp. 1700-1705 ◽  
Author(s):  
Jesper C. Madsen ◽  
Anne Q. Rasmussen ◽  
Søren D. Ladefoged ◽  
Peter Schwarz
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Hormone Secretion

Parathyroid hormone metabolism and its potential as a uremic toxin

1980 ◽  
Vol 239 (1) ◽  
pp. F1-F12 ◽  
Author(s):  
E. Slatopolsky ◽  
K. Martin ◽  
K. Hruska
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Chronic Renal Failure ◽  
Biological Effects ◽  
Uremic Toxin ◽  
Terminal Portion ◽  
Single Chain ◽  
Biochemical Alterations ◽  
Amino Terminal ◽  
Carboxy Terminal

Secondary hyperparathyroidism is a universal complication of chronic renal failure. It has been proposed that the markedly elevated levels of immunoreactive parathyroid hormone (i-PTH) in uremia may represent a “uremic toxin” responsible for many of the abnormalities of the uremic state. Plasma i-PTH consists of a mixture of intact hormone, a single-chain polypeptide of 84 amino acids, and smaller molecular weight hormonal fragments from both the carboxy- and amino-terminal portion of the PTH molecule. The hormonal fragments arise from metabolism of intact PTH by peripheral organs as well as from secretion of fragments from the parathyroid glands. The structural requirements for the known biological actions of PTH reside in the amino-terminal portion of the PTH molecule. Carboxy-terminal fragments, biologically inactive at least in terms of adenylate cyclase activation, hypercalcemia, or phosphaturia, depend on the kidney for their removal from plasma, and thus accumulate in the circulation in chronic renal failure. It is unknown at the present time if other biological effects of these carboxy-terminal fragments may contribute to some of the biochemical alterations observed in uremia. The most significant consequence of increased PTH levels in uremia is the development of bone disease characterized by osteitis fibrosa. In addition, it would appear that PTH plays an important role in some of the abnormal electroencephalographic patterns observed in uremia. This may be due to a potential role of PTH in increasing calcium content of brain. Parathyroid hormone also has been implicated as a pathogenetic factor in many other alterations present in uremia, i.e., peripheral neuropathy, carbohydrate intolerance, hyperlipidemia, and other alterations. Unfortunately, outstanding clinical research is lacking in this field and conclusive experimental data are practically nonexistent. Further studies are necessary if one is to accept the concept of PTH being a significant “uremic toxin.”

Sign in / Sign up

Export Citation Format

Share Document